BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Memon K, Lewandowski RJ, Kulik L, Riaz A, Mulcahy MF, Salem R. Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol. 2011;21:294-302. [PMID: 21939859 DOI: 10.1016/j.semradonc.2011.05.004] [Cited by in Crossref: 51] [Cited by in F6Publishing: 40] [Article Influence: 5.1] [Reference Citation Analysis]
Number Citing Articles
1 Maturen KE, Feng MU, Wasnik AP, Azar SF, Appelman HD, Francis IR, Platt JF. Imaging Effects of Radiation Therapy in the Abdomen and Pelvis: Evaluating “Innocent Bystander” Tissues. RadioGraphics 2013;33:599-619. [DOI: 10.1148/rg.332125119] [Cited by in Crossref: 50] [Cited by in F6Publishing: 36] [Article Influence: 5.6] [Reference Citation Analysis]
2 Kesim S, Ones T, Ozguven S, Dulundu E, Baltacioglu F. Selective Internal Radiation Therapy for Liver Metastasis of Papillary Thyroid Carcinoma. Clin Nucl Med 2020;45:76-7. [PMID: 31524685 DOI: 10.1097/RLU.0000000000002763] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
3 Nezami N, Kokabi N, Camacho JC, Schuster DM, Xing M, Kim HS. 90Y radioembolization dosimetry using a simple semi-quantitative method in intrahepatic cholangiocarcinoma: Glass versus resin microspheres. Nucl Med Biol 2018;59:22-8. [PMID: 29448165 DOI: 10.1016/j.nucmedbio.2018.01.001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
4 Durack JC, Hope TA, Seo Y, Saeed M, He J, Wilson MW, Kerlan RK, Ring EJ. Intravenous Vasopressin for the Prevention of Nontarget Gastrointestinal Embolization during Liver-directed Cancer Treatment: Experimental Study in a Porcine Model. Journal of Vascular and Interventional Radiology 2012;23:1505-12. [DOI: 10.1016/j.jvir.2012.07.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
5 Sulpice L, Rayar M, Boucher E, Pracht M, Meunier B, Boudjema K. Treatment of recurrent intrahepatic cholangiocarcinoma. British Journal of Surgery 2012;99:1711-7. [DOI: 10.1002/bjs.8953] [Cited by in Crossref: 71] [Cited by in F6Publishing: 67] [Article Influence: 7.1] [Reference Citation Analysis]
6 Cuestas ML, Oubiña JR, Mathet VL. Hepatocellular carcinoma and multidrug resistance: Past, present and new challenges for therapy improvement. World J Pharmacol 2015; 4(1): 96-116 [DOI: 10.5497/wjp.v4.i1.96] [Cited by in CrossRef: 2] [Article Influence: 0.3] [Reference Citation Analysis]
7 Liu D, Klass D, Westcott M, Kennedy AS. The Limitations of Theoretical Dose Modeling for Yttrium-90 Radioembolization. Journal of Vascular and Interventional Radiology 2014;25:1146-7. [DOI: 10.1016/j.jvir.2014.03.025] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
8 Adam SZ, Miller FH. Imaging of the Liver Following Interventional Therapy for Hepatic Neoplasms. Radiologic Clinics of North America 2015;53:1061-76. [DOI: 10.1016/j.rcl.2015.05.009] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
9 Dong Y, Cai Q, Fu L, Liu H, Ma M, Wu X. Study of the G Protein Nucleolar 2 Value in Liver Hepatocellular Carcinoma Treatment and Prognosis. Biomed Res Int 2021;2021:4873678. [PMID: 34337013 DOI: 10.1155/2021/4873678] [Reference Citation Analysis]
10 Rice M, Krosin M, Haste P. Post Yttrium-90 Imaging. Semin Intervent Radiol 2021;38:460-5. [PMID: 34629714 DOI: 10.1055/s-0041-1735569] [Reference Citation Analysis]
11 Galanakis N, Kehagias E, Matthaiou N, Samonakis D, Tsetis D. Transcatheter arterial chemoembolization combined with radiofrequency or microwave ablation for hepatocellular carcinoma: a review. Hepat Oncol 2018;5:HEP07. [PMID: 31293775 DOI: 10.2217/hep-2018-0001] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
12 Chan H, Lo Y, Chang D, Li J, Chang W, Chen C, Chang C, Chen C, Wang H, Liu R, Wu C. Radiometal-Labeled Chitosan Microspheres as Transarterial Radioembolization Agents against Hepatocellular Carcinoma. Gels 2022;8:180. [DOI: 10.3390/gels8030180] [Reference Citation Analysis]
13 Cruz MRS, de Lima Lopes G, dos Santos LV. Nanoknife and Hepatic Embolization for Colorectal Cancer Liver Metastases. Curr Colorectal Cancer Rep 2014;10:76-83. [DOI: 10.1007/s11888-013-0202-5] [Reference Citation Analysis]
14 Mikell JK, Dewaraja YK, Owen D. Transarterial Radioembolization for Hepatocellular Carcinoma and Hepatic Metastases: Clinical Aspects and Dosimetry Models. Semin Radiat Oncol 2020;30:68-76. [PMID: 31727302 DOI: 10.1016/j.semradonc.2019.08.005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
15 Bauer DF, Russ T, Waldkirch BI, Tönnes C, Segars WP, Schad LR, Zöllner FG, Golla AK. Generation of annotated multimodal ground truth datasets for abdominal medical image registration. Int J Comput Assist Radiol Surg 2021;16:1277-85. [PMID: 33934313 DOI: 10.1007/s11548-021-02372-7] [Reference Citation Analysis]
16 Sofocleous CT, Garcia AR, Pandit-taskar N, Do KG, Brody LA, Petre EN, Capanu M, Longing AP, Chou JF, Carrasquillo JA, Kemeny NE. Phase I Trial of Selective Internal Radiation Therapy for Chemorefractory Colorectal Cancer Liver Metastases Progressing After Hepatic Arterial Pump and Systemic Chemotherapy. Clinical Colorectal Cancer 2014;13:27-36. [DOI: 10.1016/j.clcc.2013.11.010] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 4.0] [Reference Citation Analysis]
17 Mosconi C, Cappelli A, Ascanio S, Pettinari I, Modestino F, Renzulli M, Galaverni MC, Cucchetti A, Gramenzi A, Pettinato C, Golfieri R. Yttrium-90 microsphere radioembolization in unresectable intrahepatic cholangiocarcinoma. Future Oncology 2017;13:1301-10. [DOI: 10.2217/fon-2017-0022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
18 Pérez-López A, Martín-Sabroso C, Torres-Suárez AI, Aparicio-Blanco J. Timeline of Translational Formulation Technologies for Cancer Therapy: Successes, Failures, and Lessons Learned Therefrom. Pharmaceutics 2020;12:E1028. [PMID: 33126622 DOI: 10.3390/pharmaceutics12111028] [Reference Citation Analysis]
19 Su Y, Mackey RV, Riaz A, Gates VL, Benson AB, Miller FH, Yaghmai V, Gabr A, Salem R, Lewandowski RJ. Long-Term Hepatotoxicity of Yttrium-90 Radioembolization as Treatment of Metastatic Neuroendocrine Tumor to the Liver. Journal of Vascular and Interventional Radiology 2017;28:1520-6. [DOI: 10.1016/j.jvir.2017.05.011] [Cited by in Crossref: 26] [Cited by in F6Publishing: 22] [Article Influence: 5.2] [Reference Citation Analysis]
20 Dhir M, Melin AA, Douaiher J, Lin C, Zhen WK, Hussain SM, Geschwind JF, Doyle MB, Abou-Alfa GK, Are C. A Review and Update of Treatment Options and Controversies in the Management of Hepatocellular Carcinoma. Ann Surg. 2016;263:1112-1125. [PMID: 26813914 DOI: 10.1097/sla.0000000000001556] [Cited by in Crossref: 124] [Cited by in F6Publishing: 86] [Article Influence: 24.8] [Reference Citation Analysis]
21 Hosseini SH, Enferadi M, Sadeghi M. Dosimetric aspects of 166Ho brachytherapy biodegradable glass seed. Appl Radiat Isot 2013;73:109-15. [PMID: 23313765 DOI: 10.1016/j.apradiso.2012.12.002] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
22 Gaba RC, Lakhoo J. Yttrium-90 microsphere radioembolization for treatment of lung cancer hepatic metastases. Case Rep Oncol 2012;5:479-86. [PMID: 23109925 DOI: 10.1159/000342706] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
23 Loffroy R, Ronot M, Greget M, Bouvier A, Mastier C, Sengel C, Tselikas L, Arnold D, Maleux G, Pelage JP, Pellerin O, Peynircioglu B, Sangro B, Schaefer N, Urdániz M, Kaufmann N, Bilbao JI, Helmberger T, Vilgrain V; CIRT-FR Principal Investigators. Short-term Safety and Quality of Life Outcomes Following Radioembolization in Primary and Secondary Liver Tumours: a Multi-centre Analysis of 200 Patients in France. Cardiovasc Intervent Radiol 2021;44:36-49. [PMID: 32975600 DOI: 10.1007/s00270-020-02643-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
24 Powerski MJ, Scheurig-Münkler C, Hamm B, Gebauer B. Impaired hepatic Gd-EOB-DTPA enhancement after radioembolisation of liver malignancies. J Med Imaging Radiat Oncol 2014;58:472-80. [PMID: 24964737 DOI: 10.1111/1754-9485.12187] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
25 Waddell JJ, Townsend PH, Collins ZS, Walter C. Liver-Directed Therapy for Metastatic Colon Cancer: Update. Curr Colorectal Cancer Rep 2022;18:18-25. [DOI: 10.1007/s11888-022-00474-1] [Reference Citation Analysis]
26 Xing M, Lahti S, Kokabi N, Schuster DM, Camacho JC, Kim HS. 90Y Radioembolization Lung Shunt Fraction in Primary and Metastatic Liver Cancer as a Biomarker for Survival. Clinical Nuclear Medicine 2016;41:21-7. [DOI: 10.1097/rlu.0000000000000915] [Cited by in Crossref: 16] [Cited by in F6Publishing: 7] [Article Influence: 2.7] [Reference Citation Analysis]
27 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol. 2015;7:738-752. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738].] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
28 Iezzi R, Bilhim T, Crocetti L, Peynircioglu B, Goldberg S, Bilbao JI, Sami A, Akhan O, Scalise P, Giuliante F, Pompili M, Valentini V, Gasbarrini A, Colosimo C, Manfredi R. "Primum Non Nocere" in Interventional Oncology for Liver Cancer: How to Reduce the Risk for Complications? Life (Basel) 2020;10:E180. [PMID: 32899925 DOI: 10.3390/life10090180] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Bauschke A, Altendorf-Hofmann A, Freesmeyer M, Winkens T, Malessa C, Schierz JH, Teichgraeber U, Settmacher U. [Selective internal radioembolization in nonresectable hepatocellular carcinoma]. Chirurg 2016;87:956-63. [PMID: 27460230 DOI: 10.1007/s00104-016-0259-1] [Cited by in Crossref: 5] [Article Influence: 0.8] [Reference Citation Analysis]
30 Kappadath SC, Mikell J, Balagopal A, Baladandayuthapani V, Kaseb A, Mahvash A. Hepatocellular Carcinoma Tumor Dose Response After 90Y-radioembolization With Glass Microspheres Using 90Y-SPECT/CT-Based Voxel Dosimetry. International Journal of Radiation Oncology*Biology*Physics 2018;102:451-61. [DOI: 10.1016/j.ijrobp.2018.05.062] [Cited by in Crossref: 29] [Cited by in F6Publishing: 30] [Article Influence: 7.3] [Reference Citation Analysis]
31 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015;7:738-52. [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Reference Citation Analysis]
32 Wang H, Gong G, Wang H, Li D, Yin Y, Lu J. Performance evaluations of demons and free form deformation algorithms for the liver region. Technol Cancer Res Treat 2014;13:101-8. [PMID: 23919395 DOI: 10.7785/tcrt.2012.500369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
33 James T, Hill J, Fahrbach T, Collins Z. Differences in Radiation Activity Between Glass and Resin 90Y Microspheres in Treating Unresectable Hepatic Cancer. Health Phys 2017;112:300-4. [PMID: 28121731 DOI: 10.1097/HP.0000000000000631] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
34 Reuvers TGA, Kanaar R, Nonnekens J. DNA Damage-Inducing Anticancer Therapies: From Global to Precision Damage. Cancers (Basel) 2020;12:E2098. [PMID: 32731592 DOI: 10.3390/cancers12082098] [Cited by in Crossref: 10] [Cited by in F6Publishing: 12] [Article Influence: 5.0] [Reference Citation Analysis]
35 Jamre M, Shamsaei M, Erfani M, Sadjadi S, Ghannadi Maragheh M. Preparation and evaluation of 188 Re sulfide colloidal nanoparticles loaded biodegradable poly (L-lactic acid) microspheres for radioembolization therapy. J Labelled Comp Radiopharm 2018;61:586-94. [PMID: 29644706 DOI: 10.1002/jlcr.3627] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
36 Van de Wiele C, Maes A, Brugman E, D’asseler Y, De Spiegeleer B, Mees G, Stellamans K. SIRT of liver metastases: physiological and pathophysiological considerations. Eur J Nucl Med Mol Imaging 2012;39:1646-55. [DOI: 10.1007/s00259-012-2189-6] [Cited by in Crossref: 40] [Cited by in F6Publishing: 32] [Article Influence: 4.0] [Reference Citation Analysis]
37 Sofocleous CT, Violari EG, Sotirchos VS, Shady W, Gonen M, Pandit-Taskar N, Petre EN, Brody LA, Alago W, Do RK, D'Angelica MI, Osborne JR, Segal NH, Carrasquillo JA, Kemeny NE. Radioembolization as a Salvage Therapy for Heavily Pretreated Patients With Colorectal Cancer Liver Metastases: Factors That Affect Outcomes. Clin Colorectal Cancer 2015;14:296-305. [PMID: 26277696 DOI: 10.1016/j.clcc.2015.06.003] [Cited by in Crossref: 30] [Cited by in F6Publishing: 27] [Article Influence: 4.3] [Reference Citation Analysis]
38 Golfieri R. SIR-Spheres yttrium-90 radioembolization for the treatment of unresectable liver cancers. Hepat Oncol 2014;1:265-83. [PMID: 30190962 DOI: 10.2217/hep.14.6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
39 Bas A, Samanci C, Gulsen F, Cantasdemir M, Kabasakal L, Kantarci F, Numan F. Evaluation of Liver Stiffness After Radioembolization by Real-Time ShearWave™ Elastography: Preliminary Study. Cardiovasc Intervent Radiol 2015;38:957-63. [PMID: 25413262 DOI: 10.1007/s00270-014-1021-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
40 Powerski MJ, Scheurig-münkler C, Banzer J, Schnapauff D, Hamm B, Gebauer B. Clinical practice in radioembolization of hepatic malignancies: A survey among interventional centers in Europe. European Journal of Radiology 2012;81:e804-11. [DOI: 10.1016/j.ejrad.2012.04.004] [Cited by in Crossref: 22] [Cited by in F6Publishing: 20] [Article Influence: 2.2] [Reference Citation Analysis]
41 van der Pol J, de Vos-Geelen J, Bucerius J, Mitea C, van der Leij C. Uncomplicated 90Y Selective Internal Radio Therapy in a Patient With Hepatocellular Carcinoma After Arterial and Portal Vein Embolizations. Clin Nucl Med 2018;43:180-2. [PMID: 29389772 DOI: 10.1097/RLU.0000000000001945] [Reference Citation Analysis]
42 Eisenbrey JR, Gabriel H, Savsani E, Lyshchik A. Contrast-enhanced ultrasound (CEUS) in HCC diagnosis and assessment of tumor response to locoregional therapies.Abdom Radiol (NY). 2021;46:3579-3595. [PMID: 33825927 DOI: 10.1007/s00261-021-03059-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
43 Mosconi C, Cappelli A, Pettinato C, Golfieri R. Radioembolization with Yttrium-90 microspheres in hepatocellular carcinoma: Role and perspectives. World J Hepatol 2015; 7(5): 738-752 [PMID: 25914774 DOI: 10.4254/wjh.v7.i5.738] [Cited by in Crossref: 36] [Cited by in F6Publishing: 27] [Article Influence: 5.1] [Reference Citation Analysis]
44 Rusthoven CG, Schefter TE. Rationale for ablation of oligometastatic disease and the role of stereotactic body radiation therapy for hepatic metastases. Hepat Oncol 2014;1:81-94. [PMID: 30190943 DOI: 10.2217/hep.13.12] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
45 Tsai C, Chung HT, Chu W, Cheng JC. Radiation therapy for primary and metastatic tumors of the liver. J Radiat Oncol 2012;1:227-37. [DOI: 10.1007/s13566-012-0045-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]